We are live on ! Find out more
MB

MPM BioImpact Portfolio holdings

AUM $1.64B
1-Year Est. Return 245.64%
This Fund
S&P 500
This Quarter Est. Return
+5.64%
1 Year Est. Return
+245.64%
3 Year Est. Return
+550.3%
5 Year Est. Return
+647.56%
10 Year Est. Return
–
AUM
$415M
AUM Growth
+$38.9M
Cap. Flow
+$70.4M
Cap. Flow %
16.95%
Top 10 Hldgs %
97.86%
Holding
12
New
1
Increased
1
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
ITOS
iTeos Therapeutics
ITOS
+$63.4M
2
EPZM
Epizyme, Inc
EPZM
+$7.01M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 92.38%
2 Miscellaneous 7.62%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RPTX
1
DELISTED
Repare Therapeutics
RPTX
$73.5M 17.71%
2,388,337
– –
TCRR
2
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$68.5M 16.5%
3,370,982
– –
HARP
3
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$66.2M 15.96%
389,842
– –
ITOS
4
DELISTED
iTeos Therapeutics
ITOS
$58.1M 14%
+2,355,557
New +$63.4M
EPZM
5
DELISTED
Epizyme, Inc
EPZM
$34.1M 8.21%
2,854,737
+523,203
+22% +$7.01M
TPTX
6
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$27M 6.5%
308,686
– –
ADCT icon
7
ADC Therapeutics
ADCT
$146M
$17.8M 4.29%
539,648
– –
GTHX
8
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$16.4M 3.96%
1,423,794
– –
YMAB
9
DELISTED
Y-mAbs Therapeutics
YMAB
$12.9M 3.12%
337,291
– –
MRUS
10
DELISTED
Merus
MRUS
$8.41M 2.03%
700,879
– –
AUTL
11
Autolus Therapeutics
AUTL
$623M
$463K 0.11%
39,740
– –

Similar funds

OCM
Opti Capital Management New York $1.64B AUM 0% 1-Year Est. Return
LFS
Lutz Financial Services Omaha, Nebraska $1.64B AUM 15.04% 1-Year Est. Return
TIM
Triodos Investment Management Driebergen-Rijsenburg, Netherlands $1.64B AUM 37.98% 1-Year Est. Return
AAG
Armstrong Advisory Group Needham, Massachusetts $1.64B AUM 19.37% 1-Year Est. Return
MRG
Milestone Resources Group Road Town Tortola, British Virgin Islands $1.64B AUM 2.87% 1-Year Est. Return
EPW
Evolve Private Wealth Los Angeles, California $1.64B AUM
TWM
Tradition Wealth Management Edina, Minnesota $1.64B AUM 26.59% 1-Year Est. Return
MA
MONECO Advisors Fairfield, Connecticut $1.64B AUM 25.43% 1-Year Est. Return

MPM BioImpact's Q3 2020 Portfolio in Review

As of Q3 2020, MPM BioImpact held 12 positions worth $415M, up 10% from $376M the previous quarter. Its ten largest holdings account for 98% of the portfolio.

MPM BioImpact deployed $70.4M of net new capital in Q3 2020, opening 1 new position and adding to 1 existing holding. Its largest new stake was iTeos Therapeutics: 2,355,557 shares worth $58.1M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 89% a quarter earlier, followed by Miscellaneous.

  • MPM BioImpact's largest Q3 2020 buy was iTeos Therapeutics: 2,355,557 shares worth $58.1M.
  • MPM BioImpact added most to Epizyme, Inc in Q3 2020, an estimated $7.01M increase.
  • MPM BioImpact's ten largest holdings make up 98% of its $415M portfolio in Q3 2020.
  • MPM BioImpact opened 1 new position and closed 0 in Q3 2020.
  • MPM BioImpact's portfolio value rose 10% quarter-over-quarter to $415M.

Based on MPM BioImpact's 13F filing for Q3 2020, filed 13 Nov 2020.